Waymo vs a2z Radiology AI

Side-by-side comparison of AI visibility scores, market position, and capabilities

Waymo

LeaderTransportation & Logistics

Autonomous Vehicles

Alphabet subsidiary operating 500K+ paid robotaxi rides/week across 10 US cities; raised $16B at $126B valuation in Feb 2026; expanding to 20+ new cities and London

AI VisibilityBeta
Overall Score
A80
Category Rank
#1 of 7
AI Consensus
55%
Trend
stable
Per Platform
ChatGPT
74
Perplexity
89
Gemini
78

About

Waymo is Alphabet's autonomous vehicle subsidiary and the world's most operationally advanced robotaxi company, with roots in Google's self-driving car project that began in 2009. Spun out as an independent Alphabet subsidiary, Waymo has spent over 15 years accumulating real-world driving data, refining its sensor suite (combining lidar, radar, and cameras), and developing the Waymo Driver — the AI stack that enables fully driverless operation across diverse urban environments.\n\nWaymo One, its commercial robotaxi service, operates in San Francisco, Phoenix, Los Angeles, Austin, and additional US cities, completing over 500,000 paid rides per week as of early 2026. Unlike competitors that rely on remote safety operators, Waymo vehicles operate fully autonomously on public roads. The company is also developing Waymo Via for autonomous trucking and expanding its geographic footprint through partnerships with ride-hailing platforms and automotive OEMs.\n\nWaymo raised $16B at a $126B valuation in February 2026, reflecting investor confidence in its lead position in a winner-take-most autonomous mobility market. With expansion to 20+ new cities planned, the company is transitioning from proving the technology works to demonstrating unit economics at scale. As the robotaxi market accelerates, Waymo's decade-plus operational head start, unmatched safety record, and Alphabet's resources give it a structural advantage that rivals are struggling to close.

Full profile

a2z Radiology AI

EmergingEnterprise AI

Medical Imaging AI

a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.

About

a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.